ontrolled Correspondence Related to Generic Drug Development Guidance for Industry

On 16 December 2020 the FDA published the final guidance for industry.

This guidance provides information regarding the process by which generic drug manufacturers and related industry or their representatives can submit to FDA controlled correspondence requesting information related to generic drug development. This guidance also describes the Agency’s process for providing communications related to such correspondence.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /